Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial
Official title:
A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis
This study was divided into two parts. The first part was a dose escalation study: a open label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic characteristics of ZSP1603 in IPF patients. The second part was a randomized double-blind placebo-controlled design was used to preliminatively investigate the efficacy and safety of ZSP1603 in the treatment of IPF at the target dose.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04497831 -
Morphine for Dyspnea in Pulmonary Fibrosis
|
Phase 3 | |
| Completed |
NCT01718990 -
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
|
||
| Completed |
NCT00162760 -
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
|
Phase 2 | |
| Terminated |
NCT04589260 -
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT04069143 -
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
|
Phase 1 | |
| Completed |
NCT03050255 -
Short-term Effects of Supplemental Oxygen in Patients With IPF
|
N/A | |
| Terminated |
NCT02013700 -
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
|
Phase 1 | |
| Recruiting |
NCT04598919 -
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03981094 -
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02758808 -
Pulmonary Fibrosis Foundation Patient Registry
|
||
| Not yet recruiting |
NCT05387785 -
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Recruiting |
NCT05938920 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02538536 -
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT01371305 -
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Withdrawn |
NCT03720483 -
Inhaled NAC in Treatment of IPF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03478553 -
The Genetics of Pulmonary Fibrosis
|
||
| Recruiting |
NCT05975983 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03650075 -
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03832946 -
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02874989 -
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
|
Phase 1 |